NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Chitadze, Guranda ^a   Lettau, Marcus ^a   Luecke, Stefanie ^a   Wang, Ting ^a,b   Janssen, Ottmar ^a   Fürst, Daniel ^c,d   Mytilineos, Joannis ^c,d   Wesch, Daniela ^a   Oberg, Hans Heinrich ^a   Held Feindt, Janka ^e   Kabelitz, Dieter ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF ALBERTA   (Canada)

^c German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Gamma delta T cells; glioblastoma; immunotherapy; NKG2D; T cell receptor; ULBP2

Indexed keywords

ADAM10 ENDOPEPTIDASE; ANTIGEN; BINDING PROTEIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; ILOMASTAT; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D LIGAND; PROTEIN INHIBITOR; PYROPHOSPHATE ANTIGENS; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ULBP2 PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ARTICLE; CALCEIN-AM ASSAY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALIGNANT GLIOMA CELL LINE; PROTEIN EXPRESSION; TUMOR CELL LINE;

EID: 84962798233     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1093276     Document Type: Article

References (59)

1. M.Preusser, S.de Ribaupierre, A.Wohrer, S.C.Erridge, M.Hegi, M.Weller, R.Stupp. Current concepts and management of glioblastoma. Ann Neurol 2011; 70:9-21; PMID:21786296; http://dx.doi.org/10.1002/ana.22425
2. K.Bielamowicz, S.Khawja, N.Ahmed. Adoptive cell therapies for glioblastoma. Front Oncol 2013; 3:275; PMID:24273748; http://dx.doi.org/10.3389/fonc.2013.00275
3. T.Y.Jung, Y.D.Choi, Y.H.Kim, J.J.Lee, H.S.Kim, J.S.Kim, S.K.Kim, S.Jung, D.Cho. Immunological characterization of glioblastoma cells for immunotherapy. Anticancer Res 2013; 33:2525-33; PMID:23749904
4. E.Ullrich, J.Koch, A.Cerwenka, A.Steinle. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2013; 2:e26097; PMID:24353908; http://dx.doi.org/10.4161/onci.26097
5. M.Champsaur, L.L.Lanier. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235:267-85; PMID:20536569; http://dx.doi.org/10.1111/j.0105-2896.2010.00893.x
6. D.H.Raulet, S.Gasser, B.G.Gowen, W.Deng, H.Jung. Regulation of ligands for the NKG2D activating receptor. Ann Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/annurev-immunol-032712-095951
7. L.Fernandez-Messina, O.Ashiru, S.Aguera-Gonzalez, H.T.Reyburn, M.Vales-Gomez. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. J Cell Sci 2011; 124:321-7; PMID:21224393; http://dx.doi.org/10.1242/jcs.076042
8. N.Nausch, A.Cerwenka. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
9. C.A.Crane, S.J.Han, J.J.Barry, B.J.Ahn, L.L.Lanier, A.T.Parsa. TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. NeuroOncol 2010; 12:7-13; PMID:20150362; http://dx.doi.org/10.1093/neuonc/nop009
10. W.H.Leung, Q.P.Vong, W.Lin, L.Janke, T.Chen, W.Leung. Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXR gamma activation. J Exp Med 2013; 210:2675-92; PMID:24190430; http://dx.doi.org/10.1084/jem.20122292
11. I.Waldhauer, D.Goehlsdorf, F.Gieseke, T.Weinschenk, M.Wittenbrink, A.Ludwig, S.Stevanovic, H.G.Rammensee, A.Steinle. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68:6368-76; PMID:18676862; http://dx.doi.org/10.1158/0008-5472.CAN-07-6768
12. G.Chitadze, M.Lettau, J.Bhat, D.Wesch, A.Steinle, D.Furst, J.Mytilineos, H.Kalthoff, O.Janssen, H.H.Oberg et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int J Cancer 2013; 133:1557-66; PMID:23526433; http://dx.doi.org/10.1002/ijc.28174
13. F.Wolpert, I.Tritschler, A.Steinle, M.Weller, G.Eisele. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. NeuroOncol 2014; 16:382-91; PMID:24327582; http://dx.doi.org/10.1093/neuonc/not232
14. G.Chitadze, J.Bhat, M.Lettau, O.Janssen, D.Kabelitz. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 2013; 78:120-9; PMID:23679194; http://dx.doi.org/10.1111/sji.12072
15. J.Zhang, M.F.Stevens, T.D.Bradshaw. Temozolomide: mechanisms of action, repair and resistance. CurrMolPharmacol 2012; 5:102-14; PMID:22122467; http://dx.doi.org/10.2174/1874467211205010102
16. L.S.Lamb, Jr, J.Bowersock, A.Dasgupta, G.Y.Gillespie, Y.Su, A.Johnson, H.T.Spencer. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PloS One 2013; 8:e51805; PMID:23326319; http://dx.doi.org/10.1371/journal.pone.0051805
17. C.Harly, Y.Guillaume, S.Nedellec, C.M.Peigne, H.Monkkonen, J.Monkkonen, J.Li, J.Kuball, E.J.Adams, S.Netzer et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood 2012; 120:2269-79; PMID:22767497; http://dx.doi.org/10.1182/blood-2012-05-430470
18. S.Vavassori, A.Kumar, G.S.Wan, G.S.Ramanjaneyulu, M.Cavallari, S.El Daker, T.Beddoe, A.Theodossis, N.K.Williams, E.Gostick et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol 2013; 14:908-16; PMID:23872678; http://dx.doi.org/10.1038/ni.2665
19. H.Wang, O.Henry, M.D.Distefano, Y.C.Wang, J.Räikkönen, J.Mönkkönen, Y.Tanaka, C.T.Morita. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol 2013; 191:1029-42; PMID:23833237; http://dx.doi.org/10.4049/jimmunol.1300658
20. H.J.Gober, M.Kistowska, L.Angman, P.Jeno, L.Mori, G.De Libero. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163-8; PMID:12538656; http://dx.doi.org/10.1084/jem.20021500
21. D.Kabelitz, D.Wesch, W.He. Perspectives of γδ T cells in tumor immunology. Cancer Res 2007; 67:5-8; PMID:17210676; http://dx.doi.org/10.1158/0008-5472.CAN-06-3069
22. P.Wrobel, H.Shojaei, B.Schittek, F.Gieseler, B.Wollenberg, H.Kalthoff, D.Kabelitz, D.Wesch. Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor- vs. NKG2D-dependent recognition. Scand J Immunol 2007; 66:320-8; PMID:17635809; http://dx.doi.org/10.1111/j.1365-3083.2007.01963.x
23. N.L.Bryant, G.Y.Gillespie, R.D.Lopez, J.M.Markert, G.A.Cloud, C.P.Langford, H.Arnouk, Y.Su, H.L.Haines, C.Suarez-Cuervo et al. Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme. J Neurooncol 2011; 101:179-88; PMID:20532954; http://dx.doi.org/10.1007/s11060-010-0245-2
24. O.Ashiru, P.Boutet, L.Fernandez-Messina, S.Aguera-Gonzalez, J.N.Skepper, M.Vales-Gomez, H.T.Reyburn. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010; 70:481-9; PMID:20068167; http://dx.doi.org/10.1158/0008-5472.CAN-09-1688
25. L.Fernandez-Messina, O.Ashiru, P.Boutet, S.Aguera-Gonzalez, J.N.Skepper, H.T.Reyburn, M.Vales-Gomez. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J BiolChem 2010; 285:8543-51; PMID:20080967; http://dx.doi.org/10.1074/jbc.M109.045906
26. C.Hundhausen, D.Misztela, T.A.Berkhout, N.Broadway, P.Saftig, K.Reiss, D.Hartmann, F.Fahrenholz, R.Postina, V.Matthews et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102:1186-95; PMID:12714508; http://dx.doi.org/10.1182/blood-2002-12-3775
27. N.L.Bryant, C.Suarez-Cuervo, G.Y.Gillespie, J.M.Markert, L.B.Nabors, S.Meleth, R.D.Lopez, L.S.Lamb, Jr. Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma. NeuroOncol 2009; 11:357-67; PMID:19211933; http://dx.doi.org/10.1215/15228517-2008-111
28. E.Espinosa, C.Belmant, F.Pont, B.Luciani, R.Poupot, F.Romagné, H.Brailly, M.Bonneville, J.J.Fournié. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells. J BiolChem 2001; 276: 18337-44; PMID:11279081; http://dx.doi.org/10.1074/jbc.M100495200
29. O.Janssen, S.Wesselborg, B.Heckl-Östreicher, K.Pechhold, A.Bender, S.Schondelmaier, G.Moldenhauer, D.Kabelitz. T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor γδ+ T cells. J Immunol 1991; 146:35-9; PMID:1824593
30. N.Stern-Ginossar, O.Mandelboim. An integrated view of the regulation of NKG2D ligands. Immunology 2009; 128:1-6; PMID:19689730; http://dx.doi.org/10.1111/j.1365-2567.2009.03147.x
31. S.Aguera-Gonzalez, P.Boutet, H.T.Reyburn, M.Vales-Gomez. Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol 2009; 182:4800-8; PMID:19342658; http://dx.doi.org/10.4049/jimmunol.0800713
32. S.Aguera-Gonzalez, C.C.Gross, L.Fernandez-Messina, O.Ashiru, G.Esteso, H.C.Hang, H.T.Reyburn, E.O.Long, M.Vales-Gomez. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur J Immunol 2011; 41:3667-76; PMID:21928280; http://dx.doi.org/10.1002/eji.201141645
33. M.Gooz. ADAM-17: the enzyme that does it all. Crit Rev BiochemMolBiol 2010; 45:146-69; PMID:20184396; http://dx.doi.org/10.3109/10409231003628015
34. D.F.Seals, S.A.Courtneidge. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17:7-30; PMID:12514095; http://dx.doi.org/10.1101/gad.1039703
35. M.Hedlund, O.Nagaeva, D.Kargl, V.Baranov, L.Mincheva-Nilsson. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PloS One 2011; 6:e16899; PMID:21364924; http://dx.doi.org/10.1371/journal.pone.0016899
36. H.R.Salih, S.Holdenrieder, A.Steinle. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 2008; 13:3448-56; PMID:18508446; http://dx.doi.org/10.2741/2939
37. A.M.Marleau, C.S.Chen, J.A.Joyce, R.H.Tullis. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med 2012; 10:134; PMID:22738135; http://dx.doi.org/10.1186/1479-5876-10-134
38. M.Jinushi, F.S.Hodi, G.Dranoff. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Nat AcadSci USA 2006; 103:9190-5; PMID:16754847; http://dx.doi.org/10.1073/pnas.0603503103
39. N.Kato, J.Tanaka, J.Sugita, T.Toubai, Y.Miura, M.Ibata, Y.Syono, S.Ota, T.Kondo, M.Asaka et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 2007; 21:2103-8; PMID:17625602; http://dx.doi.org/10.1038/sj.leu.2404862
40. B.Huang, R.Sikorski, P.Sampath, S.H.Thorne. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 2011; 34:289-96; PMID:21389869; http://dx.doi.org/10.1097/CJI.0b013e31820e1b0d
41. U.Lendeckel, J.Kohl, M.Arndt, S.Carl-McGrath, H.Donat, C.Röcken. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res ClinOncol 2005; 131:41-8; PMID:15565459; http://dx.doi.org/10.1007/s00432-004-0619-y
42. M.J.Duffy, E.McKiernan, N.O'Donovan, P.M.McGowan. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15:1140-4; PMID:19228719; http://dx.doi.org/10.1158/1078-0432.CCR-08-1585
43. L.Witters, P.Scherle, S.Friedman, J.Fridman, E.Caulder, R.Newton, A.Lipton. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 2008; 68:7083-9; PMID:18757423; http://dx.doi.org/10.1158/0008-5472.CAN-08-0739
44. M.D.Groves, V.K.Puduvalli, K.R.Hess, K.A.Jaeckle, P.Peterson, W.K.Yung, V.A.Levin. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J ClinOncol 2002; 20:1383-8; PMID:11870183; http://dx.doi.org/10.1200/JCO.20.5.1383
45. M.D.Groves, V.K.Puduvalli, C.A.Conrad, M.R.Gilbert, W.K.Yung, K.Jaeckle, V.Liu, K.R.Hess, K.D.Aldape, V.A.Levin. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 2006; 80:83-90; PMID:16639492; http://dx.doi.org/10.1007/s11060-006-9160-y
46. S.Rose-John. ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res 2013; 71:19-22; PMID:23415892; http://dx.doi.org/10.1016/j.phrs.2013.01.012
47. W.Deng, B.G.Gowen, L.Zhang, L.Wang, S.Lau, A.Iannello, J.Xu, T.L.Rovis, N.Xiong, D.H.Raulet. Antitumor immunity.A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 2015; 348:136-9; PMID:25745066; http://dx.doi.org/10.1126/science.1258867
48. D.F.Angelini, R.Zambello, R.Galandrini, A.Diamantini, R.Placido, F.Micucci, F.Poccia, G.Semenzato, G.Borsellino, A.Santoni et al. NKG2A inhibits NKG2C effector functions of γδ T cells: implications in health and disease. J LeukocBiol 2011; 89: 75-84; PMID:20952657; http://dx.doi.org/10.1189/jlb.0710413
49. H.Shojaei, H.H.Oberg, M.Juricke, L.Marischen, M.Kunz, C.Mundhenke, F.Gieseler, D.Kabelitz, D.Wesch. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γδ T cells. Cancer Res 2009; 69:8710-7; PMID:19887600; http://dx.doi.org/10.1158/0008-5472.CAN-09-1602
50. O.Toutirais, F.Cabillic, G.LeFriec, S.Salot, P.Loyer, M.Le Gallo, M.Desille, C.T.de LaPintiere, P.Daniel, F.Bouet et al. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vg9Vd2 T cells. Eur J Immunol 2009; 39:1361-8; PMID:19404979; http://dx.doi.org/10.1002/eji.200838409
51. C.E.Fadul, J.L.Fisher, J.Gui, T.H.Hampton, A.L.Cote, M.S.Ernstoff. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. NeuroOncol 2011; 13:393-400; PMID:21339188; http://dx.doi.org/10.1093/neuonc/noq204
52. J.Jin, K.M.Joo, S.J.Lee, M.Y.Jo, Y.Kim, Y.Jin, J.K.Kim, J.M.Ahn, M.J.Yoon, J.Lim et al. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep 2011; 25:33-9; PMID:21109954; http://dx.doi.org/10.3892/or_00001038
53. J.Bennouna, E.Bompas, E.M.Neidhardt, F.Rolland, I.Philip, C.Galea, S.Salot, S.Saiagh, M.Audrain, M.Rimbert et al. Phase-I study of Innacellγδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer ImmunolImmunother 2008; 57:1599-609; PMID:18301889; http://dx.doi.org/10.1007/s00262-008-0491-8
54. Y.Abe, M.Muto, M.Nieda, Y.Nakagawa, A.Nicol, T.Kaneko, S.Goto, K.Yokokawa, K.Suzuki. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. ExpHematol 2009; 37:956-68; PMID:19409955; http://dx.doi.org/10.1016/j.exphem.2009.04.008
55. H.Kobayashi, Y.Tanaka, J.Yagi, Y.Osaka, H.Nakazawa, T.Uchiyama, N.Minato, H.Toma. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer ImmunolImmunother 2007; 56:469-76; PMID:16850345; http://dx.doi.org/10.1007/s00262-006-0199-6
56. A.J.Nicol, H.Tokuyama, S.R.Mattarollo, T.Hagi, K.Suzuki, K.Yokokawa, M.Nieda. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011; 105:778-86; PMID:21847128; http://dx.doi.org/10.1038/bjc.2011.293
57. H.H.Oberg, M.Peipp, C.Kellner, S.Sebens, S.Krause, D.Petrick, S.Adam-Klages, C.Röcken, T.Becker, I.Vogel et al. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Cancer Res 2014; 74:1349-60; PMID:24448235; http://dx.doi.org/10.1158/0008-5472.CAN-13-0675
58. H.R.Salih, H.Antropius, F.Gieseke, S.Z.Lutz, L.Kanz, H.G.Rammensee, A.Steinle. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-96; PMID:12714493; http://dx.doi.org/10.1182/blood-2003-01-0019
59. S.Neri, E.Mariani, A.Meneghetti, L.Cattini, A.Facchini. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. ClinDiagnLaboImmunol 2001; 8:1131-5; PMID:11687452; http://dx.doi.org/10.1128/CDLI.8.6.1131–1135.2001